Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

BACKGROUND AND OBJECTIVES: Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evaluated in various malignancies. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Ken, Newhall, Kathryn, Maxwell, Stephen E., Dell’Aringa, Justine, Komashko, Vitalina, Kilavuz, Nurgul, Delarue, Richard, Czuczman, Myron, Sternas, Lars, Rose, Shelonitda, Beach, C. L., Novick, Steven, Zhou, Simon, Palmisano, Maria, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007418/
https://www.ncbi.nlm.nih.gov/pubmed/31332669
http://dx.doi.org/10.1007/s40262-019-00804-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007418/
https://www.ncbi.nlm.nih.gov/pubmed/31332669
http://dx.doi.org/10.1007/s40262-019-00804-x

Ejemplares similares